Shannon Thyme Klinger is Chief Legal Officer of Moderna, Inc.. Currently has a direct ownership of 25,612 shares of MRNA, which is worth approximately $896,676. The most recent transaction as insider was on Mar 07, 2025, when has been sold 551 shares (Common Stock) at a price of $34.3 per share, resulting in proceeds of $18,899. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.6K
25.27% 3M change
176.38% 12M change
Total Value Held $896,676

Shannon Thyme Klinger Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 07 2025
SELL
Payment of exercise price or tax liability
$18,899 $34.3 p/Share
551 Reduced 2.11%
25,612 Common Stock
Mar 07 2025
BUY
Exercise of conversion of derivative security
-
1,139 Added 4.17%
26,163 Common Stock
Feb 28 2025
SELL
Payment of exercise price or tax liability
$8,487 $31.09 p/Share
273 Reduced 1.08%
25,024 Common Stock
Feb 28 2025
BUY
Exercise of conversion of derivative security
-
562 Added 2.18%
25,184 Common Stock
Feb 27 2025
SELL
Payment of exercise price or tax liability
$93,318 $33.58 p/Share
2,779 Reduced 10.1%
24,735 Common Stock
Feb 27 2025
BUY
Exercise of conversion of derivative security
-
5,747 Added 18.09%
26,018 Common Stock
Feb 12 2025
SELL
Payment of exercise price or tax liability
$33,033 $30.93 p/Share
1,068 Reduced 4.75%
21,425 Common Stock
Feb 12 2025
BUY
Grant, award, or other acquisition
-
2,047 Added 8.34%
22,493 Common Stock
Dec 09 2024
SELL
Open market or private sale
$23,635 $44.68 p/Share
529 Reduced 2.52%
20,446 Common Stock
Dec 06 2024
BUY
Exercise of conversion of derivative security
-
1,138 Added 5.15%
20,975 Common Stock
Dec 03 2024
SELL
Open market or private sale
$4,849 $43.3 p/Share
112 Reduced 0.56%
19,837 Common Stock
Dec 02 2024
BUY
Exercise of conversion of derivative security
-
232 Added 1.15%
19,949 Common Stock
Nov 29 2024
SELL
Open market or private sale
$60,676 $42.79 p/Share
1,418 Reduced 6.71%
19,717 Common Stock
Nov 27 2024
BUY
Exercise of conversion of derivative security
-
2,981 Added 12.36%
21,135 Common Stock
Sep 09 2024
SELL
Open market or private sale
$40,537 $73.57 p/Share
551 Reduced 2.95%
18,154 Common Stock
Sep 06 2024
BUY
Exercise of conversion of derivative security
-
1,139 Added 5.74%
18,705 Common Stock
Sep 03 2024
SELL
Open market or private sale
$8,776 $76.99 p/Share
114 Reduced 0.64%
17,566 Common Stock
Aug 30 2024
BUY
Exercise of conversion of derivative security
-
233 Added 1.3%
17,680 Common Stock
Aug 29 2024
SELL
Open market or private sale
$12,640 $78.03 p/Share
162 Reduced 0.92%
17,447 Common Stock
Aug 28 2024
SELL
Open market or private sale
$104,715 $79.39 p/Share
1,319 Reduced 7.09%
17,280 Common Stock
Aug 28 2024
BUY
Exercise of conversion of derivative security
-
329 Added 1.83%
17,609 Common Stock
Aug 27 2024
BUY
Exercise of conversion of derivative security
-
2,652 Added 12.48%
18,599 Common Stock
Jun 10 2024
SELL
Open market or private sale
$766,810 $148.09 p/Share
5,178 Reduced 24.51%
15,947 Common Stock
Jun 07 2024
BUY
Exercise of conversion of derivative security
-
10,247 Added 32.66%
21,125 Common Stock
Jun 03 2024
SELL
Open market or private sale
$17,167 $140.72 p/Share
122 Reduced 1.11%
10,878 Common Stock

Also insider at

RFL
Rafael Holdings, Inc. Real Estate
STK

Shannon Thyme Klinger

Chief Legal Officer
Cambridge, MA

Track Institutional and Insider Activities on MRNA

Follow Moderna, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRNA shares.

Notify only if

Insider Trading

Get notified when an Moderna, Inc. insider buys or sells MRNA shares.

Notify only if

News

Receive news related to Moderna, Inc.

Track Activities on MRNA